Chemours Co (CC) Shares Bought by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP raised its holdings in Chemours Co (NYSE:CC) by 1.1% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 707,349 shares of the specialty chemicals company’s stock after buying an additional 7,604 shares during the quarter. Dimensional Fund Advisors LP owned 0.38% of Chemours worth $35,798,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in CC. Acrospire Investment Management LLC grew its holdings in shares of Chemours by 3.4% during the 2nd quarter. Acrospire Investment Management LLC now owns 3,076 shares of the specialty chemicals company’s stock worth $117,000 after purchasing an additional 100 shares in the last quarter. Gamco Investors INC. ET AL acquired a new stake in shares of Chemours during the 3rd quarter worth approximately $202,000. Aull & Monroe Investment Management Corp acquired a new stake in shares of Chemours during the 3rd quarter worth approximately $204,000. Essex Financial Services Inc. acquired a new stake in shares of Chemours during the 3rd quarter worth approximately $204,000. Finally, Argyle Capital Management Inc. acquired a new stake in shares of Chemours during the 3rd quarter worth approximately $210,000. 74.34% of the stock is currently owned by hedge funds and other institutional investors.

Chemours Co (NYSE CC) opened at $52.47 on Friday. The company has a current ratio of 2.19, a quick ratio of 1.63 and a debt-to-equity ratio of 5.07. The company has a market capitalization of $9,700.00 and a P/E ratio of 36.19. Chemours Co has a 52-week low of $23.39 and a 52-week high of $58.08.

Chemours (NYSE:CC) last posted its earnings results on Thursday, November 2nd. The specialty chemicals company reported $1.12 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.01 by $0.11. The business had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.59 billion. Chemours had a return on equity of 116.80% and a net margin of 4.86%. Chemours’s revenue was up 13.3% on a year-over-year basis. During the same quarter last year, the company earned $0.61 EPS. analysts forecast that Chemours Co will post 3.65 earnings per share for the current fiscal year.

Chemours declared that its Board of Directors has initiated a stock buyback plan on Friday, December 1st that allows the company to repurchase $500.00 million in shares. This repurchase authorization allows the specialty chemicals company to buy shares of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board believes its stock is undervalued.

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 15th. Investors of record on Thursday, February 15th will be given a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a dividend yield of 1.30%. The ex-dividend date of this dividend is Wednesday, February 14th. This is an increase from Chemours’s previous quarterly dividend of $0.03. Chemours’s dividend payout ratio (DPR) is 8.28%.

In other Chemours news, insider Christian W. Siemer sold 15,088 shares of Chemours stock in a transaction on Wednesday, December 13th. The stock was sold at an average price of $47.37, for a total value of $714,718.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider E Bryan Snell sold 11,878 shares of Chemours stock in a transaction on Monday, November 6th. The shares were sold at an average price of $53.25, for a total value of $632,503.50. Following the completion of the transaction, the insider now owns 63,063 shares of the company’s stock, valued at approximately $3,358,104.75. The disclosure for this sale can be found here. 1.14% of the stock is owned by company insiders.

Several brokerages have recently weighed in on CC. Barclays reissued a “buy” rating and set a $60.00 price objective on shares of Chemours in a report on Wednesday, December 6th. Zacks Investment Research lowered Chemours from a “buy” rating to a “hold” rating in a report on Wednesday, December 6th. Goldman Sachs Group lowered Chemours from a “buy” rating to a “neutral” rating and set a $55.00 price objective on the stock. in a report on Wednesday, December 6th. UBS Group lifted their price objective on Chemours from $50.00 to $59.00 and gave the stock a “neutral” rating in a report on Friday, November 3rd. Finally, Jefferies Group lifted their price objective on Chemours to $66.00 and gave the stock a “buy” rating in a report on Monday, December 4th. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Chemours has an average rating of “Buy” and an average price target of $57.89.

ILLEGAL ACTIVITY WARNING: “Chemours Co (CC) Shares Bought by Dimensional Fund Advisors LP” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/01/14/chemours-co-cc-shares-bought-by-dimensional-fund-advisors-lp.html.

Chemours Profile

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemours Co (NYSE:CC).

Institutional Ownership by Quarter for Chemours (NYSE:CC)

Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply